Browse the corpus

REFERENCES Alexandroff AB, Jackson AM, O'Donnell MA, et al, “BCG Immunotherapy of Bladder Cancer: 20 Years On,” Lancet , 1999, 353(9165):1689-94. [PubMed 10335805 ] Badalament RA and Farah RN, “Treatment of Superficial Bladder Cancer With Intravesical Chemotherapy,” Semin Surg Oncol , 1997, 13(5):335-41. [PubMed 9259089 ] Bassi P, “BCG (Bacillus of Calmette Guerin) Therapy of High-Risk Superficial Bladder Cancer,” Surg Oncol , 2002, 11(1-2):77-83. [PubMed 12031870 ] Centers for Disease Control and Prevention (CDC), “Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,” MMWR Recomm Rep , 2011, 60(2):1-64. [PubMed 21293327 ] Centers for Disease Control and Prevention (CDC), “Syncope After Vaccination -- United States, January 2005-July 2007,” MMWR Morb Mortal Wkly Rep , 2008, 57(17):457-60. Available at file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5717a2.htm [PubMed 18451756 ] Centers for Disease Control and Prevention,“TB Elimination: BCG Vaccine,” November 2008. Available at file://www.cdc.gov/tb/publications/factsheets/prevention/BCG.htm Centers for Disease Control and Prevention,“The Role of BCG Vaccine in the Prevention and Control of Tuberculosis in the United States: A Joint Statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices,” MMWR Recomm Rep , 1996, 45(RR-4):1-18. Available at file://www.cdc.gov/mmwr/PDF/rr/rr4504.pdf [PubMed 8602127 ] Lamm DL, Steg A, Boccon-Gibod L, et al, “Complications of Bacillus Calmette-Guérin Immunotherapy: Review of 2602 Patients and Comparison of Chemotherapy Complications,” Prog Clin Biol Res , 1989, 310:335-55. [PubMed 2505273 ] Martinez-Pineiro JA and Martinez-Pineiro L, “BCG Update: Intravesical Therapy,” Eur Urol , 1997, 31(Suppl 1):31-41. [PubMed 9076484 ] Meyer JP, Persad R, and Gillatt DA, “Use of Bacille Calmette-Guerin in Superficial Bladder Cancer,” Postgrad Med J , 2002, 78(922):449-54. [PubMed 12185215 ] Nathanson L, “Use of BCG in the Treatment of Human Neoplasms: A Review,” Semin Oncol , 1974, 1(4):337-50. [PubMed 4620439 ] National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Bladder Cancer,” Version 2.2012. Available at file://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf

Nathanson L, “Use of BCG in the Treatment of Human Neoplasms: A Review,” Semin Oncol , 1974, 1(4):337-50. [PubMed 4620439 ] National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Bladder Cancer,” Version 2.2012. Available at file://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Nseyo UO and Lamm DL, “Immunotherapy of Bladder Cancer,” Semin Surg Oncol , 1997, 13(5):342-9. [PubMed 9259090 ] Prymula R, Siegrist CA, Chlibek R, et al, “Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,” Lancet , 2009, 374(9698):1339-50. [PubMed 19837254 ] Rischmann P, Desgrandchamps F, Malavaud B, et al, “BCG Intravesical Instillations: Recommendations for Side-Effects Management,” Eur Urol , 2000, 37(Suppl 1):33-6. [PubMed 10575271 ] Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, “Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,” Pediatrics , 2008, 121(6):1281-6. [PubMed 18519501 ] Topic 9063 Version 46.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1104-122.72.76.133-62E4DD783C-S244013.14]